Two Harbors Investment Corp (TWO) announced a quarterly dividend of $0.34 per share, maintaining its distribution levels, which yields an 11.04%. Despite this, the company has a low GF Score™ of 32/100, indicating significant weaknesses in financial strength and profitability. Insiders have also sold $0.1 million worth of shares in the past three months, raising concerns among investors about the company's future outlook, especially with ongoing negotiations for a potential all-cash offer from UWMC.

Trinity Biotech plc has filed a prospectus supplement (424B3) registering the secondary resale of up to 33,752,429 ADSs by selling shareholders. This filing incorporates a recent Form 6-K which reported a 43% year-on-year revenue increase to $10.8M for Q1 2026, an improved gross margin of 35.4%, and a narrowed net loss of $4.4M, with adjusted EBITDA at -$1.1M. The company also announced significant purchase orders for over 2 million TrinScreen HIV tests to be fulfilled in Q3 2026, indicating strong commercial traction.

TTEC Digital has achieved Platinum Partner status in the NiCE 360 VISION Partner Program, the highest tier in NiCE's partner ecosystem. This recognition highlights TTEC Digital's strategic alignment with NiCE's agentic AI vision and its proven ability to deliver transformative customer experience outcomes, including cloud migration savings and AI-powered contact center modernization. The company is also a launch partner for the upcoming NiCE AI Specialization Program, further cementing its leadership in AI-driven CX innovation.

Boeing has been awarded an $880 million firm-fixed-price contract by the U.S. Navy to procure, modernize, and sustain P-8A Poseidon aircrew and maintenance training systems. This long-term contract signifies ongoing demand in the defense sector, with work expected to be completed by June 2031. The project will enhance fleet readiness and provides Boeing with stable revenue streams, positively impacting its future financial performance.

Amazon is facing a class action lawsuit alleging it broke promises to consumers about keeping prices low during the Trump administration's tariff period. The lawsuit, filed by Howard Rosen, claims Amazon passed tariff costs onto consumers, increasing prices by over 5% between January and July 2025, a higher rate than competitors. Rosen argues Amazon failed to honor its commitments and seeks to represent a nationwide class of consumers for damages and injunctive relief.

Hologic, Inc. has published its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's commitment to improving women's health globally and details significant progress in environmental goals, including reducing operational emissions and water usage, and increasing renewable energy reliance. Hologic's initiatives have impacted over 199 million lives in 2025 through its women's health solutions and community engagement efforts.

CarMax (NYSE: KMX) stock saw a significant 13% rebound on Thursday, following a 9% loss in the previous trading session after its first-quarter fiscal 2027 results. The turnaround was driven by several positive post-earnings analyst notes, including a notable upgrade from Stephens pundit Jeff Lick, who raised his outlook to "overweight" (buy) and substantially increased his price target to $66 per share. Analysts at JPMorgan Chase and Baird also adjusted their price targets, indicating a more bullish sentiment for the auto retailer.

Alliant Energy's "Second Nature" program allows customers to voluntarily opt-in to purchasing wind and solar energy credits, reshaping their power bills by matching a portion of their consumption with renewable sources. While it doesn't physically reroute electrons, it procures and retires renewable energy certificates, contributing to grid decarbonization. This initiative offers a simple way for climate-conscious households to support clean energy without large upfront investments, complementing Alliant Energy's broader strategy of large-scale renewable projects.

Insulet Corp. (PODD) stock rose 1.56% to $145.76, outperforming the broader market on a strong trading day where the S&P 500 and Dow Jones Industrial Average also saw gains. This positive movement ended a three-day losing streak for the company's shares.

Quoin Pharmaceuticals has established a wholly-owned subsidiary in Japan to support the direct commercialization of QRX003 for Netherton Syndrome, following the recent grant of Orphan Drug Designation by Japan's MHLW. This move is part of Quoin's strategy to self-commercialize in key territories, including the U.S. and Western Europe. QRX003 is currently in Phase 2 clinical trials, with a Phase 3 study planned for late 2026 and a potential NDA filing in 2027, aiming to become the first approved treatment for Netherton Syndrome.